Esperion Therapeutics (ESPR) Operating Margin (2019 - 2026)
Esperion Therapeutics (ESPR) posted Operating Margin of 8.22% for Q1 2026, down 116.24% on a QoQ basis from 50.6% in Q4 2025, and up 2578.0% year-over-year from 0.31% in Q1 2025.
Esperion Therapeutics (ESPR) Operating Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics' Operating Margin history runs 8 years deep, the most recent figure standing at 8.22% for Q1 2026.
- Quarterly Operating Margin rose 2578.0% year-over-year to 8.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18.12% (up 3352.0% YoY) and the FY2025 annual result came in at 14.95%, down 142.0% from the prior year.
- Operating Margin was 8.22% for Q1 2026 at Esperion Therapeutics, down from 50.6% in the prior quarter.
- Across five years, Operating Margin topped out at 52.47% in Q1 2024 and bottomed at 277.99% in Q2 2022.
- A 5-year average of 87.25% and a median of 34.0% in 2025 frame the typical range for Operating Margin.
- Peak annual rise in Operating Margin reached 80993 bps in 2022, while the deepest fall reached 19798 bps in 2022.
- Esperion Therapeutics' Operating Margin stood at 225.92% in 2022, then soared by 42 bps to 131.37% in 2023, then soared by 95 bps to 6.4% in 2024, then jumped by 891 bps to 50.6% in 2025, then sank by 116 bps to 8.22% in 2026.
- Business Quant data shows ESPR's Operating Margin at 8.22% in Q1 2026, 50.6% in Q4 2025, and 11.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -8.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.22% |
| Dec 31, 2025 | 50.60% |
| Sep 30, 2025 | -11.41% |
| Jun 30, 2025 | 8.61% |
| Mar 31, 2025 | -34.00% |
| Dec 31, 2024 | -6.40% |
| Sep 30, 2024 | -31.04% |
| Jun 30, 2024 | 3.49% |
| Mar 31, 2024 | 52.47% |
| Dec 31, 2023 | -131.37% |
| Sep 30, 2023 | -81.05% |
| Jun 30, 2023 | -143.71% |
| Mar 31, 2023 | -199.78% |
| Dec 31, 2022 | -225.92% |
| Sep 30, 2022 | -219.30% |
| Jun 30, 2022 | -277.99% |
| Mar 31, 2022 | -228.23% |
| Dec 31, 2021 | -361.20% |
| Sep 30, 2021 | -386.88% |
| Jun 30, 2021 | -80.01% |